High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphoma (PTCL): Analysis of Prognostic Factors

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 10, 2011, Pages 1481-1489

  Nademanee, Auayporn ^a   Palmer, Joycelynne M ^a   Popplewell, Leslie ^a   Tsai, Ni Chun ^a   Delioukina, Maria ^a   Gaal, Karl ^a   Cai, Ji lian ^b   Kogut, Neil ^b   Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

Autologous stem cell transplantation; Peripheral t cell lymphoma

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; MELPHALAN; PREDNISONE; STEROID; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILD; DRUG MEGADOSE; FEMALE; FOLLOW UP; HIGH DOSE THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRESCHOOL CHILD; PROGNOSIS; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CHILD; CHILD, PRESCHOOL; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MELPHALAN; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 80053004898     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.02.008     Document Type: Article

References (29)

1. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392.
2. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee MeetingAirlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835-3849.
3. Melnyk A., Rodriguez A., Pugh W.C., Cabannillas F. Evaluation of the revised European-American Lymphoma Classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997, 89:4514-4520.
4. Gisselbrecht C., Gaulard P., Lepage E., et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 1998, 92:76-82.
5. Rudiger T., Weisenburger D.D., Anderson J.R., et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's lymphoma classification project. Ann Oncol 2002, 13:140-149.
6. International T Cell Lymphoma Project International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008, 26:4124-4130.
7. Savage K.J., Harris N.L., Vose J.M., et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008, 111:5496-5504.
8. Gallamini A., Stelitano C., Calvi R., et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004, 103:2474-2479.
9. Rodriguez J., Caballero M.D., Gutierrez A., et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003, 14:1768-1775.
10. Kewalramani T., Zelenetz A.D., Teruya-Feldstein J., et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006, 134:202-207.
11. Feyler S., Prince H.M., Pearce R., et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007, 40:443-450.
12. Corradini P., Tarella C., Zallio F., et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006, 20:1533-1538.
13. Mercadal S., Briones J., Xicoy B., et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008, 19:958-963.
14. Rodriguez J., Conde E., Gutierrez A., et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007, 18:652-657.
15. Reimer P., Rudiger T., Geissinger E., et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009, 27:106-113.
16. Shipp M.A. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-994.
17. Breslow N.E., Day N.E. Statistical methods in cancer research: volume II, the design and analysis of cohort studies. IARC Sci Publ 1987, 82:1-406.
18. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
19. Gray R.J. A class of K-sample tests of comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16.
20. Cox D.R. Regression models and life tables. J R Stat Soc 1972, B34:187-220.
21. Jagasia M., Morgan D., Goodman S., et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 2004, 45:2261-2267.
22. Rodriguez J., Conde E., Gutierrez A., et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the GEL-TAMO study Group. Eur J Haematol 2007, 79:32-38.
23. Rodriguez J., Munsell M., Yazji S., et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001, 19:3766-3770.
24. Rodriguez J., Caballero M.D., Gutierrez A., et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy.The GEL-TAMO experience. Haematologica 2003, 88:1372-1377.
25. Yang D.H., Kim W.S., Kim S.J., et al. Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transplant 2009, 15:118-125.
26. Haioun C., Lepage E., Gisselbrecht C., et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol-AGroupe d'Etude des Lymphomes de l'Adulte Study. J Clin Oncol 2000, 18:3025-3030.
27. d'Amore F., Relander T., Lauritzsen G., et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-cell lymphomas (PTCL)-a phase II study of the Nordic Lymphoma Group (NLG). ASH Annu Meet Abstr 2006, 108:401.
28. Corradini P., Dodero A., Zallio F., et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004, 22:2172-2176.
29. Le Gouill S., Milpied N., Buzyn A., et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008, 26:2264-2271.